Literature DB >> 10366100

Dominant-negative p53 mutations in rheumatoid arthritis.

Z Han1, D L Boyle, Y Shi, D R Green, G S Firestein.   

Abstract

OBJECTIVE: Studies were performed to determine if p53 mutations identified in rheumatoid arthritis (RA) synovial tissue are dominant negative.
METHODS: Site-directed mutagenesis was used to produce 2 RA-derived mutants: asparagine-->serine at codon 239 (N239S) and arginine-->stop at codon 213 R213*). HS68 dermal fibroblasts were transfected with either empty vector, wild-type p53 cDNA (wt), or the N239S or R213* mutant p53 cDNA clones. Interleukin-6 (IL-6) and bax gene expression were determined by Northern blot analysis. Bax transcription was determined using a bax promoter/reporter gene construct (bax-luc).
RESULTS: Transfection of HS68 cells with wt increased bax mRNA levels. This process was blocked by cotransfection with either mutant. The mutant p53 genes also increased IL-6 gene expression. Low levels of bax promoter activity were detected in HS68 cells co-transfected with bax-luc and empty vector, N239S, or R213*, indicating that the RA mutants lacked transcriptional activity. Transfection with wt and bax-luc led to a 10-fold increase in luciferase expression. When the wt gene was cotransfected with either of the mutants, there was a dose-dependent inhibition of bax promoter activity.
CONCLUSION: These data indicate that at least 2 of the p53 mutants identified in RA joint samples are dominant negative and suppress endogenous wild-type p53 function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366100     DOI: 10.1002/1529-0131(199906)42:6<1088::AID-ANR4>3.0.CO;2-E

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

Authors:  H Taubert; B Thamm; A Meye; F Bartel; A K Rost; D Heidenreich; V John; J Brandt; M Bache; P Würl; H Schmidt; D Riemann
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Authors:  Matthew J Scheffel; Gina Scurti; Patricia Simms; Elizabeth Garrett-Mayer; Shikhar Mehrotra; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

Review 3.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.

Authors:  Nunzio Bottini; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

4.  Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis.

Authors:  Yuji Yamanishi; David L Boyle; Michael J Pinkoski; Artin Mahboubi; Tesu Lin; Zuoning Han; Nathan J Zvaifler; Douglas R Green; Gary S Firestein
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 5.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

6.  Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue.

Authors:  Bruno Stuhlmüller; Elke Kunisch; Juliane Franz; Lorena Martinez-Gamboa; Maria M Hernandez; Axel Pruss; Norbert Ulbrich; Volker A Erdmann; Gerd R Burmester; Raimund W Kinne
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

7.  Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

Authors:  R Chauhan; R Handa; T P Das; U Pati
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

8.  Regional analysis of p53 mutations in rheumatoid arthritis synovium.

Authors:  Yuji Yamanishi; David L Boyle; Sanna Rosengren; Douglas R Green; Nathan J Zvaifler; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

Review 9.  Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.

Authors:  Gyrid Nygaard; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2020-05-11       Impact factor: 20.543

10.  Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis.

Authors:  J Schedel; O Distler; M Woenckhaus; R E Gay; B Simmen; B A Michel; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.